EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Dynamic Precision Oncology for Real-Time Molecular Monitoring and Management in Urothelial Carcinoma

Whi-An Kwon iD, Yeon Jee Lee iD, Yong Sang Song iD

International Journal of Molecular Sciences · 13.04.2026 · 27 (8) · 3474

DOI: 10.3390/ijms27083474 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 13.04.2026. Verfasst von Whi-An Kwon und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hanyang University College of Medicine, Myongji Hospital, Goyang 10475, Republic of Korea. Hauptthemen laut MEDLINE: Precision Medicine, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The management of urothelial carcinoma (UC) is undergoing a paradigm shift from static anatomical staging to molecularly guided dynamic approaches that integrate time as a critical therapeutic variable. This evolution is driven by liquid biopsies, particularly circulating tumor DNA, which allow real-time tumor interrogation. We conducted this expert review to synthesize landmark evidence, enabling technologies, and implementation challenges in dynamic precision oncology for UC. In this non-systematic narrative review, we searched PubMed/MEDLINE, Embase, Web of Science, and the Cochrane Library for articles published between January 2015 and February 2026. Studies were selected based on their relevance to dynamic precision oncology, clinical actionability, and translational implementation, prioritizing landmark randomized controlled trials providing level 1–2 evidence, large prospective cohorts, and key translational studies. Enfortumab vedotin plus pembrolizumab established the new first-line standard for metastatic UC, achieving a median overall survival of 33.8 months versus 15.9 months (hazard ratio [HR] 0.51, 95% confidence interval 0.43–0.61). Circulating tumor DNA demonstrates robust prognostic value for molecular residual disease (MRD) detection (Level 2a evidence), stratifying recurrence risk with hazard ratios of approximately 4.5. Critically, the IMvigor011 trial has now provided Level 1b evidence that ctDNA-guided adjuvant atezolizumab improves both disease-free survival (DFS) (HR 0.64, p = 0.0047) and OS (HR 0.59, p = 0.0131) in ctDNA(+) patients, while validating treatment de-escalation in ctDNA(−) patients (1-year DFS 95%). Erdafitinib in patients harboring FGFR2/3 alterations (HR 0.64) confirms the value of genomic profiling. Major limitations include the inherent selection bias of this non-systematic approach, substantial platform heterogeneity, and lack of standardization. In conclusion, dynamic precision oncology has transformed UC management, with the IMvigor011 trial establishing ctDNA-guided MRD status as the first phase 3-validated predictive biomarker framework for adjuvant therapy selection in a solid tumor. Implementation requires adherence to established standardization frameworks, cross-platform and cross-agent validations, and tiered implementation strategies to ensure equitable access across diverse resource settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineCarcinoma, Transitional CellUrinary Bladder NeoplasmsHumansCirculating Tumor DNALiquid BiopsyBiomarkers, TumorPrognosisAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

circulating tumor DNAdynamic precision oncologyfibroblast growth factor receptorliquid biopsymolecular residual diseaseurothelial carcinoma

Substanzen

Circulating Tumor DNABiomarkers, TumorAntibodies, Monoclonal, Humanizedpembrolizumab

Autor:innen und Institutionen

  • Department of Urology, Hanyang University College of Medicine, Myongji Hospital, Goyang 10475, Republic of Korea.
  • Research Institute of Precision Medicine and Geroscience, Myongji Medical Foundation, Goyang 10475, Republic of Korea.
  • Department of Obstetrics and Gynecology, Hanyang University College of Medicine, Myongji Hospital, Goyang 10475, Republic of Korea.

ORCID-Profile: Whi-An Kwon, Yeon Jee Lee, Yong Sang Song

Zitieren

APA

Kwon, W. A., Lee, Y. J., & Song, Y. S. (2026). Dynamic Precision Oncology for Real-Time Molecular Monitoring and Management in Urothelial Carcinoma. International Journal of Molecular Sciences, 27(8), 3474. https://doi.org/10.3390/ijms27083474

Vancouver

Kwon WA, Lee YJ, Song YS. Dynamic Precision Oncology for Real-Time Molecular Monitoring and Management in Urothelial Carcinoma. International Journal of Molecular Sciences. 2026;27(8):3474. doi:10.3390/ijms27083474

BibTeX
@article{Kwon2026,
  author = {Kwon, Whi-An and Lee, Yeon Jee and Song, Yong Sang},
  title = {Dynamic Precision Oncology for Real-Time Molecular Monitoring and Management in Urothelial Carcinoma},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {8},
  pages = {3474},
  doi = {10.3390/ijms27083474}
}
Kostenlos starten →